Braveheart Bio, Inc. (BRVE)
Nasdaq · Healthcare · Biotechnology
$21.35+0.38%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $1.9B
- 52-week range
- $19.83 – $32.00
- 52-week change
- −28.62%
- EPS (trailing)
- −$6.08
- Analyst rating
- 1.0 Strong buy
- Next earnings
- Nov 12, 2026
About Braveheart Bio, Inc.
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.
Headquarters: San Francisco, United States · 49 employees · braveheart.bio